Glyscend Therapeutics
Glyscend develops a revolutionary approach to treating type 2 diabetes.
About Glyscend Therapeutics
Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. The company's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
Company Facts
- Headquarters
- Baltimore
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00001_00010
- Funding Stage
- early_stage_venture
- Total Funding
- $21,728,669
- Last Funding Type
- series_a
- Last Funding Date
- 2020-06-11
- Website
- glyscend.com
Industries & Categories
Biopharma, Biotechnology, Cosmetic Surgery, Landscaping, Medical, Pharmaceutical, Therapeutics
Social Links
Canonical: https://fsome.com/organization/glyscend-therapeutics-11576 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.